Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
MSH2 and breast cancer are reported together in 2 articles.
Gene
MSH2
- HGNC
- HGNC:7325
24articles
24mentions
0variants with confirmed gene link
Most co-reported phenotypes (articles)
Phenotype
Breast cancer
1,211articles
1,211mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
2 records shown · first 60Diverse mediators of cancer predisposition uncovered by germline whole genome sequencing of unexplained familial cancers.
PMID 42180381 | PMCID PMC13193157 | DOI 10.64898/2026.05.08.26352653 · medRxiv : the preprint server for health sciences · 2026 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | MSH2 | “We identified allelic series of rare structural variants inactivating MSH2 in individuals with phenotypes consistent with Lynch syndrome and BRCA1 in breast cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “We identified allelic series of rare structural variants inactivating MSH2 in individuals with phenotypes consistent with Lynch syndrome and BRCA1 in breast cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “We identified allelic series of rare structural variants inactivating MSH2 in individuals with phenotypes consistent with Lynch syndrome and BRCA1 in breast cancer.” | 0.98 | hgnc_dict_v1 |
| gene | TSTD2 | “Exome-wide rare variant analyses nominated six candidate predisposition genes, including TSTD2 and BRAT1 in thyroid and breast cancer, respectively.” | 0.98 | hgnc_dict_v1 |
Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients.
PMID 33868589 | PMCID PMC8021026 | DOI 10.18632/oncotarget.27909 · Oncotarget · 2021 · 14 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | MSH2 | “Among the genes analyzed, the highest mutation rates were found in PIK3CA (12.9%), BRCA2 (11.7%), BRCA1 (10.2%), TP53 (6.0%), MSH2 (3.8%), PMS2 (3.8%), BARD1 (3.8%), MLH1 (3.4%), CDH1 (3.0%), RAD50 (3.0%), MSH6 (3.0%), NF1 (2.6%), in addition to others.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | PIK3CA | “Among the genes analyzed, the highest mutation rates were found in PIK3CA (12.9%), BRCA2 (11.7%), BRCA1 (10.2%), TP53 (6.0%), MSH2 (3.8%), PMS2 (3.8%), BARD1 (3.8%), MLH1 (3.4%), CDH1 (3.0%), RAD50 (3.0%), MSH6 (3.0%), NF1 (2.6%), in addition to others.” | 0.98 | hgnc_dict_v1 |
| gene | BRCA2 | “Among the genes analyzed, the highest mutation rates were found in PIK3CA (12.9%), BRCA2 (11.7%), BRCA1 (10.2%), TP53 (6.0%), MSH2 (3.8%), PMS2 (3.8%), BARD1 (3.8%), MLH1 (3.4%), CDH1 (3.0%), RAD50 (3.0%), MSH6 (3.0%), NF1 (2.6%), in addition to others.” | 0.98 | hgnc_dict_v1 |